Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The primary goal of this study is to determine if people with metastatic melanoma who receive Heat Shock Protein-Peptide Complex - 96 (HSPPC-96 or Oncophage) after surgery live longer than people who may or may not have surgery but who receive conventional chemotherapy including IL-2/DTIC. A second goal is to determine the safety and frequency of side effects in subjects who receive therapy with HSPPC-96.
Condition or disease
Drug: HSPPC-96 or Oncophage
To determine whether subjects with stage IV melanoma randomized to HSPPC-96 have longer survival than subjects randomized to physician's choice including interleukin-2 and/or dacarbazine/temozolomide and/or complete tumor resection.
To determine frequency of adverse events in subjects randomized to HSPPC-96.
A Phase III Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus Physician's Choice Including Interleukin-2 and/or Dacarbazine/Temozolomide-based Therapy and/or Complete Tumor Resection in Stage IV Melanoma
Study Start Date
Actual Primary Completion Date
Actual Study Completion Date
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
(The following assessments must be obtained within three weeks prior to randomization into the study)
Medical history and physical examination (including EGOG score, evidence of immunosuppression);
CT/MRI of the chest, abdomen and pelvis;
CT/MRI of the brain;
Complete Blood Count with differential including platelets;
Electrolytes (Na, Cl, K, HCO3, Ca, Mg, PO4);
Renal function tests (BUN and creatinine);
Liver function tests (bilirubin, AST, ALT);
Serum pregnancy test for all women of childbearing potential.
Stage IV Melanoma (AJCC);
No prior therapy for stage IV melanoma;
No prior therapy with interleukin-2 and/or dacarbazine/temozolomide within the past 12 months prior to study entry;
Candidate for surgical resection of some/all sites of melanoma and expected to obtain greater tan or equal to 7 grams of viable cancer tissue (in aggregate), which is equivalent to a greater than or equal to 2 cm lesion on CT/MRI or clinical examination;
No brain metastases;
ECOG score 0 or 1;
Adequate cardiac function;
Adequate hematopoietic, liver and renal function;
Female subjects of child-bearing potential must agree to use contraception during the study
Signed written informed consent.
Mucosal or ocular melanomas;
Other malignancies treated within the last five years, except in situ cervix carcinoma or non-melanoma skin cancer;
Primary or secondary immunodeficiency, in the opinion of the investigator (including immunosuppressive disease, or use of systemic corticosteroids or other immunosuppressive medications);
Uncontrolled infection or other serious medical illnesses;
Women who are pregnant or breast-feeding;
Subjects participating in any other studies requiring administration of an investigational drug/biologic agent.